Immunomic Therapeutics, Inc.
Berat, Southern Albania, Albania · Biotechnology · 50 employees
The privately-held biotechnology company is pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors. It has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors, including colorectal, pancreatic, mesothelioma, ovarian and breast cancer.
Funding history
- Venture - Series Unknown — $6.5M — Jun 2025
- Venture - Series Unknown — $3.0M — Apr 2024
- Venture - Series Unknown — $77.7M — Jan 2021
- Venture - Series Unknown — $10.0M — Feb 2020
- Venture - Series Unknown — $315K — Aug 2018
Recent signals
- Jun 02, 2025: Raised $6.5M in Venture - Series Unknown
- Nov 06, 2024: Launched Immunomic Therapeutics, Inc. presents its UNITE® platform for RNA vaccines at SITC 39th Annual Meeting 2024.
- Apr 10, 2024: Raised $3.0M in Venture - Series Unknown
- Jan 14, 2021: Raised $77.7M in Venture - Series Unknown
- Feb 26, 2020: Raised $10.0M in Venture - Series Unknown
- Aug 03, 2018: Raised $315K in Venture - Series Unknown
- Mar 15, 2017: Raised $77.7M in Venture - Series Unknown
See plans & pricing → Track Immunomic Therapeutics, Inc.’s funding, hiring, and signals — with verified contacts — on Fundz.